Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Esperion Therapeutics, Inc. (ESPR)
|
Add to portfolio |
|
|
|
| Price: |
$5.19
| | Metrics |
| OS: |
94.7
|
M
| |
|
|
| Market cap: |
$492
|
M
| |
|
|
|
Net debt:
|
$98
|
M
| |
|
|
|
EV:
|
$590
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($206)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 78.4 | 227.5 | 148.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -65.5% | 53.4% | | | | | | |
| Cost of goods sold | 14.2 | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 64.2 | 225.2 | 148.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 81.9% | 98.9% | 100.0% | | | | | |
| Selling, general and administrative | 185.0 | 199.6 | 65.9 | 33.1 | | | | |
| Research and development | 106.0 | 146.9 | 175.6 | 171.5 | 147.6 | 57.9 | 29.8 | 25.3 |
| General and administrative | | | | | 21.4 | 18.3 | 20.2 | 10.9 |
| EBIT | -226.7 | -121.4 | -93.1 | -204.6 | -169.0 | -76.2 | -50.0 | -36.2 |
| EBIT margin | -289.0% | -53.3% | -62.8% | | | | | |
| Pre-tax income | -269.1 | -143.6 | -97.2 | -201.8 | -167.0 | -75.0 | -49.8 | -36.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -269.1 | -143.6 | -97.2 | -201.8 | -167.0 | -75.0 | -49.8 | -36.4 |
| Net margin | -343.0% | -63.1% | -65.5% | | | | | |
| |
| Diluted EPS | ($9.31) | ($5.23) | ($3.59) | ($7.54) | ($6.98) | ($3.33) | ($2.26) | ($2.22) |
| Shares outstanding (diluted) | 28.9 | 27.5 | 27.1 | 26.8 | 23.9 | 22.5 | 22.0 | 16.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|